Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05998759
Other study ID # BJ-2021-235
Secondary ID BJ-2021-235RCTAI
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date October 2023
Est. completion date December 2025

Study information

Verified date September 2023
Source Beijing Hospital
Contact Xuan Zhang, MD.
Phone +86-01085136736
Email zxpumch2003@sina.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to evaluate the efficacy and safety of Telitacicept for the treatment of connective tissue disease-associated thrombocytopenia.


Description:

In this randomized, double-blind placebo-controlled study, the investigators aim to evaluate the efficacy and safety of Telitacicept for the treatment of connective tissue disease-associated thrombocytopenia. After screening, eligible participants will be randomized at a 1: 1 ratio to receive either subcutaneous Telitacicept 160 mg or placebo once a week for 24 weeks. The background standard therapy is maintained stable during the whole treatment period.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 296
Est. completion date December 2025
Est. primary completion date December 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Subjects who have been diagnosed with connective tissue disease (CTD)-associated thrombocytopenia. And CTD includes primary Sjögren syndrome (according to the 2002 American College of Rheumatology (ACR)/ European League against Rheumatism (EULAR) classification criteria), systemic lupus erythematosus (SLE, according to the 1997 or the 2009 ACR classification criteria), and undifferentiated connective tissue disease (according to the 1999 international classification criteria) - Refractory thrombocytopenia defined as: Either: Failure to maintain sustained remission after treatment by oral glucocorticoid dose =1 mg/kg/day for at least 4 weeks (prednisone or equivalent) and at least one immunosuppressant (i.e. cyclophosphamide, cyclosporine, mycophenolate mofetil, azathioprine, tacrolimus, methotrexate, leflunomide and hydroxychloroquine, et al.) Or: Relapse during oral glucocorticoid tapering or after withdrawal - 50×10^9/L>PLT =20×10^9/L - anti-nuclear antibody (ANA) positive (=1:80, any karyotype) detected in the laboratory of each research center - Standard therapy should be maintained stable for at least 28 days prior to the first dose of the experimental drug or placebo. Standard therapy refers to the following treatment (monotherapy or in combination): glucocorticoid, hydroxychloroquine, and other immunosuppressants (i.e. cyclophosphamide, cyclosporine, mycophenolate mofetil, azathioprine, tacrolimus, methotrexate and leflunomide, et al.) - Signed informed consent form, willing or able to participate in all required study evaluations and procedures Exclusion Criteria: - Vital organ lethal bleeding (including but not limited to central nervous system bleeding, digestive tract bleeding) at screening, or intracranial bleeding 6 months prior to screening - Antiphospholipid syndrome, thrombotic thrombocytopenia purpura, hemolytic uremic syndrome, or thrombocytopenia secondary to other causes (such as sepsis, Epstein-Barr virus infection, cytomegalovirus infection, Corona Virus Disease-19 (COVID-19) infection, drugs, etc.) - Hematopoietic system disorders, such as myelodysplastic syndrome, paroxysmal sleep hemoglobinuria, aplastic anemia, leukemia, lymphoma, myelofibrosis and so on - Severe cardiovascular system disease, including: unstable or uncontrollable disease or condition affecting the function of the heart (such as angina pectoris, congestive heart failure, uncontrolled hypertension or arrhythmia) - Arteriovenous thromboembolism events - Receiving antiplatelet or anticoagulant therapy at screening - Clinically significant electrocardiogram changes - corrected Q-T interval (QTc)>450ms for male, QTc>470ms for female - Severe pulmonary disease, including: unstable or uncontrollable disease or condition affecting respiratory function [e.g., diffuse alveolar hemorrhage, severe pulmonary hypertension, severe pulmonary interstitial disease (peripheral blood oxygen saturation <92% at rest without oxygen, or forced vital capacity (FVC)<50%, or carbon monoxide diffusing capacity (DLCO)<50%)] - Severe kidney disease, including: severe lupus nephritis (urinary protein > 6 g/24 hours or endogenous creatinine clearance < 30 ml /min) 8 weeks prior to randomization, active nephritis requiring current protocol disallowed drugs, severe renal insufficiency requiring hemodialysis or prednisone =100mg/ day (or equivalent) for =14 days - SLE or non-SLE related central nervous system disease (including epilepsy, psychosis, organic encephalopathy syndrome, cerebrovascular accident, encephalitis, central nervous system vasculitis) 8 weeks prior to randomization - Active hepatitis, a history of severe liver disease. Subjects positive for hepatitis B surface antigen (HBsAg) or antibodies to hepatitis C virus are excluded. As for subjects with antibodies to hepatitis B core antigen (HBcAb), further hepatitis B virus (HBV)-DNA should be tested. If HBV-DNA is negative, subjects could be enrolled; otherwise, subjects should be excluded - Abnormal laboratory results (including but not limited to: alanine aminotransferase (ALT) or aspertate aminotransferase (AST)=3×ULN (upper limit of normal), white blood cell count <1.5×10^9/L) - Subjects with known active infections (e.g., shingles, COVID-19, HIV, active tuberculosis, etc.), and active or recurrent gastrointestinal ulcers - Pregnant or lactating women, and subjects with a during plan during the trial - Allergic reaction: history of allergic reactions to human biological products - Treatment with B cell-targeting agents such as Rituximab or Epratuzumab or Belimumab six months prior to randomization - Treatment with tumor necrosis factor (TNF) inhibitors or TNF-receptor blockers six months prior to randomization - Participating in clinical trial 28 days or 5 drug half-lives of the investigational agents prior to randomization - Received live vaccine 28 days prior to randomization - Treatment with thrombopoietin receptor agonists such as Eltrombopag or Romiplostim 28 days prior to randomization - Subjects with depression or suicidal thoughts - Previous treatment with telitacicept - B cell targeting drug therapy is not tolerated or responsive - Investigator considers candidates not appropriating for the study

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Telitacicept
subcutaneous telitacicept 160 mg weekly for 24 weeks.
Drug:
Placebo
subcutaneous placebo weekly for 24 weeks.

Locations

Country Name City State
China Beijing Hospital Beijing Beijing
China Peking University People's Hospital Beijing Beijing
China Peking University Third Hospital Beijing Beijing
China Second Xiangya Hospital of Central South University Changsha Hunan
China Xiangya Hospital of Central South University Changsha Hunan
China West China Hospital Chengdu Sichuan
China First Affiliated Hospital, Sun Yat-Sen University Guangzhou Guangdong
China Guangdong Provincial People's Hospital Guangzhou Guangdong
China The First Affiliated Hospital of China University of Science and Technology (Anhui Provincial) Hefei Anhui
China The Affiliated Hospital of Inner Mongolia Medical University Hohhot Inner Mongolia Autonomous Region
China Shandong Provincial Hospital Jinan Shandong
China The First People's Hospital of Yunnan Kunming Yunnan
China Changhai Hospital Shanghai Shanghai
China RenJi Hospital Shanghai Shanghai
China First Hospital of China Medical University Shenyang Liaoning
China Shanxi Bethune Hospital Taiyuan Shanxi
China Institute of Hematology & Blood Diseases Hospital Tianjin Tianjin
China Tianjin First Central Hospital Tianjin Tianjin
China Tianjin Medical University General Hospital Tianjin Tianjin
China People's Hospital of Xinjiang Uygur Autonomous Region Ürümqi Xinjiang Uygur Autonomous Region
China Wuhan Union Hospital, China Wuhan Hubei
China The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan

Sponsors (22)

Lead Sponsor Collaborator
Beijing Hospital Changhai Hospital, First Affiliated Hospital, Sun Yat-Sen University, First Hospital of China Medical University, Guangdong Provincial People's Hospital, Institute of Hematology & Blood Diseases Hospital, China, Peking University People's Hospital, Peking University Third Hospital, People's Hospital of Xinjiang Uygur Autonomous Region, RenJi Hospital, Second Xiangya Hospital of Central South University, Shandong Provincial Hospital, Shanxi Bethune Hospital, The Affiliated Hospital of Inner Mongolia Medical University, The First Affiliated Hospital of China University of Science and Technology (Anhui Provincial), The First Affiliated Hospital of Zhengzhou University, The First People's Hospital of Yunnan, Tianjin First Central Hospital, Tianjin Medical University General Hospital, West China Hospital, Wuhan Union Hospital, China, Xiangya Hospital of Central South University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other life quality 1 According to the ITP Patient Assessment Questionnaire™ (ITP-PAQ™) score. The ITP-PAQ™ is a disease-specific instrument that was designed to measure the Quality of Life (QoL) of adult patients with immune thrombocytopenia. The items employ a 4-week recall with responses recorded on 4-, 5- or 7-point Likert scales. All item scores are transformed to a 0 to 100 continuum where higher scores represent better QoL and are weighted equally to derive the scale scores. at week 24
Other life quality 2 According to the FACT-Th6 score. The Functional Assessment of Cancer Therapy-Thrombocytopenia (FACT-Th6) consists of 6 questions in which patients rate (0-4) their general degree of worry related to bleeding and bruising, and resulting activity impairment and frustration. Items were reverse-scored as necessary such that higher scores represent higher Health-related quality of life (HRQoL). Total scores ranged from 0 to 24. Recall period is previous 7 days. at week 24
Other Absolute change rate from baseline in serum immunoglobulin G (IgG) (serum IgG level at week 24-serum IgG level at baseline)/ serum IgG level at baseline at week 24
Other Absolute change rate from baseline in serum immunoglobulin M (IgM) (serum IgM level at week 24-serum IgM level at baseline)/ serum IgM level at baseline at week 24
Other Absolute change rate from baseline in serum immunoglobulin A (IgA) (serum IgA level at week 24-serum IgA level at baseline)/ serum IgA level at baseline at week 24
Other Absolute change rate from baseline in serum C3 (serum C3 level at week 24-serum C3 level at baseline)/ serum C3 level at baseline at week 24
Other Absolute change rate from baseline in serum C4 (serum C4 level at week 24-serum C4 level at baseline)/ serum C4 level at baseline at week 24
Other Absolute change rate from baseline in serum anti-platelet antibody (serum anti-platelet antibody level at week 24-serum anti-platelet antibody level at baseline)/ serum anti-platelet antibody level at baseline at week 24
Other Absolute change rate from baseline in serum Blys (serum Blys level at week 24-serum Blys level at baseline)/ serum Blys level at baseline. Blys is short for B lymphocyte stimulator. at week 24
Other Absolute change rate from baseline in serum APRIL (serum APRIL level at week 24-serum APRIL level at baseline)/ serum APRIL level at baseline. APRIL is short for a proliferation-inducing ligand. at week 24
Other Absolute change rate from baseline in peripheral naive B cell count (peripheral naive B cell count at week 24-peripheral naive B cell count at baseline)/ peripheral naive B cell count at baseline. at week 24
Other Absolute change rate from baseline in peripheral plasma cell count (peripheral plasma cell count at week 24-peripheral plasma cell count at baseline)/ peripheral plasma cell count at baseline. at week 24
Other Absolute change rate from baseline in peripheral plasmablast count (peripheral plasmablast count at week 24-peripheral plasmablast count at baseline)/ peripheral plasmablast count at baseline. at week 24
Primary Overall response (CR + PR) rate Response is deemed as complete (CR) if the platelet (PLT) count is = 100×10^9/L, partial (PR) if the platelet count ranges from 50×10^9/L to 100×10^9/L and at least doubled from baseline. No active bleeding is allowed in participants classified as CR or PR. at week 24
Secondary Overall response (CR + PR) rate Response is deemed as complete (CR) if the platelet count is = 100×10^9/L, partial (PR) if the platelet count ranges from 50×10^9/L to 100×10^9/L and at least doubled from baseline. No active bleeding is allowed in participants classified as CR or PR. at week 12
Secondary Rescue treatment rate Rescue treatment is initiated if the platelet count is <10×10^9/L, or the participant is with active bleeding, or based on the investigator's judgement when the platelet count ranges from 10×10^9/L to 20×10^9/L. at week 24
Secondary Time to rescue treatment Time to rescue treatment refers to period duration from the initiation of Telitacicept or placebo (day 1) to rescue treatment. at week 24
Secondary Relapse rate No response refers to the platelet count is < 50×10^9/L, or increases for less than 1-fold from baseline, or with active central nervous system or digestive tract bleeding, or rescue treatment is initiated. Relapse is defined as no response recurring after a complete or partial response lasting for at least 7 days with treatment. at week 24
Secondary Time to relapse Time to relapse refers to period duration from the initiation of Telitacicept or placebo (day 1) to relapse. at week 24
Secondary treatment related adverse event According to the NCI CTCAE 5.0 at week 24
Secondary treatment related severe adverse event According to the NCI CTCAE 5.0 at week 24
Secondary bleeding scale According to the ITP bleeding scale (IBLS). The IBLS comprises of 11 grades from 0 (none) to 2 (marked bleeding) by history over the previous week or by exam; 2 being worse. These 11 grades include: skin by physical exam, oral by physical exam, skin by history, oral by history, epistaxis, gastrointestinal, urinary, gynecological, pulmonary, intracranial hemorrhage, and subconjunctival hemorrhage. at week 24
See also
  Status Clinical Trial Phase
Recruiting NCT04003220 - Idiopathic Chronic Thrombocytopenia of Undetermined Significance : Pathogenesis and Biomarker
Completed NCT02948283 - Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia Phase 1
Recruiting NCT03633019 - High-dose Use of rhTPO in CIT Patients Phase 4
Recruiting NCT06087198 - Clinical Performance Evaluation of T-TAS®01 HD Chip
Recruiting NCT03605511 - TTP and aHUS in Complicated Pregnancies
Active, not recruiting NCT03688191 - Study of Sirolimus in CTD-TP in China Phase 4
Completed NCT02845609 - Efficacy of Sialic Acid GNE Related Thrombocytopenia Phase 2
Recruiting NCT02241031 - Megakaryocytic Progenitor Cells for Prophylaxis and Treatment of Thrombocytopenia Phase 2/Phase 3
Recruiting NCT02244658 - Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic Leukemia Phase 3
Unknown status NCT01196884 - Immune Thrombocytopenia (ITP) Immune-Genetic Assessment
Terminated NCT01368211 - Mirasol-Treated Platelets - (Pathogen Reduction Extended Storage Study) Phase 2/Phase 3
Completed NCT01356576 - Effect of Hemodialysis Membranes on Platelet Count N/A
Completed NCT00039858 - Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin Phase 4
Completed NCT00787241 - Platelet Count Trends in Pre-eclamptic Parturients N/A
Completed NCT00001533 - Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders With Cyclosporine Phase 1
Not yet recruiting NCT06036966 - The Efficacy and Safety of Hetrombopag in Primary Prevention of Thrombocytopenia Induced by the Niraparib Maintenance in Advanced Ovarian Cancer Patients Phase 2
Completed NCT01791101 - Eltrombopag in Patients With Delayed Post Transplant Thrombocytopenia. Phase 2
Recruiting NCT06053021 - Antiplatelet Therapy for AIS Patients With Thrombocytopenia N/A
Recruiting NCT03701217 - Eltrombopag Used in Thrombocytopenia After Comsolidation Therapy in AML Phase 2/Phase 3
Not yet recruiting NCT05958511 - Assessment of Risk Factors and Outcome of Thrombocytopenia in ICU Patients